Insights into mCRPC in China, Thailand and Indonesia - expert discussion

Bookmark and Share
Published: 21 Mar 2014
Views: 3460
Prof Rainy Umbas, Prof Narin Voravud and Prof Li Ping Xie

Speaking to ecancer from the Academy for Cancer Education (ACE) 3rd Asia Pacific Prostate Cancer Conference (APPCC) in Shanghai, Prof Rainy Umbas from the University of Indonesia, Jakarta, Indonesia, interviews Prof Narin Voravud from Chulalongkorn University Hospital, Bangkok, Thailand, and Prof Li Ping Xie from Zhejiang University School of Medicine, Hangzhou, China.

The experts first comment on local available treatment choices for mCRPC in their respective countries. The importance of diagnosing prostate cancer sooner is emphasised by the experts, since a high proportion are not found until the late stage disease at present.

The experts discuss how local policies differ from guidelines in Europe and America due to the lack of availability currently of newer drugs, such as abiraterone. However, the importance of treating patients individually, according to the evidence available and to international standards, was stressed.

They then discuss new treatments on the horizon in their respective countries, e.g. radium-223, and how these will affect treatment decision-making. The promise of benefit that enzalutamide may bring to prostate cancer care in the region is emphasised, although the challenges of sequencing are raised.

The experts finally discuss how treatment choices should be made, including in the growing number of elderly patients in the region, and the importance of multi-disciplinary teams in treatment choices.

This video is sponsored by an educational grant from Janssen Asia Pacific, pharmaceutical companies of Johnson & Johnson